Biomap (Beijing) Intelligent Technology Co., Ltd.

10月15日，苏州日报头版文章《园区：向“高”而行，产业攀登不止步》关注园区一个个高端领域实现突破，一家家强链补链延链的企业加速涌现，一款款产品走向世界。 这段时间，国家生物药技术创新中心、国家第三代半导体技术创新中心（苏州）建设现场热火朝天，来回穿梭的建筑工人忙着加快地下室底板施工，机器轰鸣声、钢筋敲击声交织回荡，汇聚成一曲项目建设的“秋日交响曲”。 两大创新平台全力冲刺建设目标，是苏州工业园区瞄准高科技、追求高效能、迈向高质量，走好创新驱动的内涵型增长之路的缩影。随着一个个高端领域实现突破、一家家强链补链延链的企业加速涌现、一款款产品走向世界，这片创新热土的产业日益勃发着高质量发展的强劲脉动。 技术向新，企业向上，产业向高。苏州工业园区，朝着建设“开放创新的世界一流高科技园区”加速跑。 告别“卡脖子” 关键核心技术屡屡突破 IPO降温，风投谨慎。在融资环境偏紧的大背景下，初创型企业“钱景”如何？ 成立32天后，就获得来自BV百度风投的天使轮融资，随后，国内首家生物计算平台百图生科参与进来。去年，医药领域风投遇冷的情况下，仍旧拿到了近2亿元A+轮融资……它，就是国内TCR-T免疫治疗的破局者——新景智源生物科技（苏州）有限公司。 年仅4岁，新景智源凭什么获得十多家资本大佬的青睐？对此，公司联合创始人、首席科学官安多的回答是：硬核技术实力。 成立于2020年9月，新景智源2022年就开发出超高灵敏度的靶点-TCR发现+验证平台，破解了行业最大的技术壁垒，填补了世界在这一领域的空白。安多介绍，公司的技术平台集靶点发现和验证于一体，具有高通量、高灵敏度的特点，这意味着TCR类药物的开发从“大海捞针”变得“有章可循”。 掌握科技创新主动权 占据未来发展制高点 这两年 园区集成电路、生物医药 纳米技术应用、人工智能等领域 关键核心技术屡屡实现突破 ▶ 纳微科技完全自主大规模生产均匀性高性能纳米微球，打破了国外垄断，近期，企业自主研发的高性能层析介质还成功实现了对三款进口介质的替代。 ▶ 海谱瑞德最近发布的桌面式柔性测试系统（DFAT）和标准ISP烧录测试机，宣告企业技术水平已位居全球第一方阵，补上区域集成电路产业生态重要一环。 ▶ 吉天星舟自主研发的新一代光学遥感卫星“苏州一号”成功飞天，标志着我国在商业航天新型对地观测技术方面取得重大突破…… 创新成果频现 掀起了园区打好 关键核心技术攻坚战的新一轮浪潮 “我们按照产业图谱靶向招商、根据产业集群建设梯次培育，并高水平建设‘一区两中心’等创新策源平台，不断放大创新对产业发展的支撑效应。”园区科技创新委员会相关负责人说。 今年1月至9月 ♦ 园区新增科技项目超千个，新申报园区科技领军项目1733个、同比增长9%，5家企业入选“2023中国独角兽企业”名单、占全市28%。 ♦ 新增国家级专精特新企业61家、占全市30%。国家生物药技术创新中心“揭榜挂帅”技术攻关项目立项89个。 ♦ 国家第三代半导体技术创新中心（苏州）在国际上率先突破了6英寸单晶衬底等一批前沿技术。 ♦ 国家新一代人工智能创新发展试验区核心区积极承接国家战略任务，加快实现以企业为主体的核心技术攻关突破。 在创新链和产业链深度融合中 园区产业集群正加速实现 质的有效提升和量的合理增长 企业领头 抱团攻坚刷新“创新进度条” 创新不是“独角戏”，而是“大合唱”。面对高水平科技自立自强这个时代命题，园区以“龙头带动，链上发力”的创新联合体，探索出了一套新打法。 8月底 苏州生物医药领域 首个生态融合型创新联合体 苏州市介入医疗技术创新联合体 亮出发展“成绩单” 成立一年多来，联合体获批1个新产品，产出2项新材料，实现3个项目进展，建设4个创新载体平台，投资了5家创新企业，孵化6个项目，吸纳7家新成员，申请专利24项，形成了“1234567”的创新成果。 这令人惊艳的研发速度 新在上下一心的高效率 更新在体制机制的创新 苏州市介入医疗技术创新联合体由园区自主培育的高端医疗器械企业沛嘉医疗牵头成立，成员单位包括知名高校、医院、创新型领军企业、生命科技产业孵化、运营和投资平台等。“创新联合体以市场机制为纽带，以自愿互利为原则，通过不断激发企业科技创新活力和内生动力，形成体系化、任务型协同创新模式。”沛嘉医疗相关负责人说。 企业是科技创新的主体，也是经济发展的动力之源。处于龙头地位的链主企业联手伙伴干大事，让“物理合并”催生“化学反应”，可加快打通“技术攻关-成果转化-创业孵化-产业培育”全链条。 目前，园区共立项 ◈ 江苏省创新联合体4家，占全省近30%。 ◈ 苏州市创新联合体21家，占全市30%，涵盖生物医药、人工智能、纳米技术等战略性新兴产业。 ◈ 在今年6月举行的第六届长三角一体化发展高层论坛上，首批12个长三角创新联合体成立。其中，由园区大模型企业思必驰科技股份有限公司牵头建设的长三角语言计算创新联合体成为苏州唯一入选单位。 由企业牵头开展科技攻关，意味着项目从一开始就紧贴市场。借助“组团创新”，园区已累计形成有效发明专利超2.5万件、高价值发明专利约1.2万件。接下来，园区将进一步加快构建以企业为主体、市场为导向、产学研结合的技术创新体系，引导创新型领军企业、行业龙头骨干企业牵头整合产业链上下游资源，共同组建体系化、任务型的创新合作组织和利益共同体，加快实现高水平科技自立自强。 生态“破圈” 助力企业海外“跑马圈地” 在推进高水平对外开放，构建双循环新发展格局征途上，越来越多企业走出国门，积极参与全球竞争。在稳居中国生物医药“第一方阵”的园区，一大批本土药企正被世界“看到”，不断“走出去”。 6月中旬，亚盛医药宣布与日本武田（Takeda）签署了一项独家选择权协议，就公司具有best-in-class潜力的第三代BCR-ABL酪氨酸激酶抑制剂（TKI）耐立克®（奥雷巴替尼）达成独家许可协议。 根据该选择权协议的条款，亚盛医药将于协议签署后收到1亿美元的选择权付款，并有资格获得最高约12亿美元的选择权行使费以及额外的潜在里程碑付款，刷新了小分子药物授权的纪录。 这不是一次简单的授权。事实上，武田的普纳替尼正是耐立克®在国际上的两大竞争对手之一。来自竞争对手的背书，更加凸显了耐立克®优质的疗效及安全性。 吸引生物医药及大健康企业超2000家 33所中外知名院校 15家“国家队”科研院所“扎堆” 依托辖区高校院所、创新企业等各类创新要素集聚的优势，园区的创新合作网络不断完善，科技成果的转移转化链条顺畅运转。在整个创新生态的良性驱动和循环中，越来越多的企业实现“破圈”发展。目前，园区企业累计获得新药临床批件971张、医疗器械注册证1816张，累计获批新药33款，2023年产值达1523亿元。 助力企业“出海无忧、行稳致远”，作为全国跨境双向投资最为活跃的地区之一，今年，园区还聚焦企业出海发展需求，创新推出“企业出海一件事”。据悉，“出海一件事”包括构建一支队伍、打造一个专区、建强一个矩阵、链接一批站点、搭建一系列赋能平台等“五个一”举措。 “我们希望通过资源集聚、队伍凝聚、平台汇聚，为企业提供集成化、一站式、全方位的增值服务，加速构建从境内到境外、从出海前到出海后的全链条、多领域、跨地域的企业出海全生命周期服务体系。”园区行政审批局相关负责人说 ▌文章来源：苏州工业园区发布 责编：赵家帅 审核：任旭 推荐阅读 《新华日报》头版：打通从实验室到市场“最后一公里” 中国新闻周刊关注！BioBAY：保持定力和韧劲往前冲 《新华日报》整版关注园区：面向世界，群英荟萃秀风华

BEIJING, Oct. 15, 2024 /PRNewswire/ -- DBN Group, a leading high-tech agricultural enterprise, has opened its Phoenix International Innovation Park for global applications from high-quality agricultural biotech companies. This initiative seeks to establish an open innovation and entrepreneurship ecosystem by harnessing cutting-edge technologies and international collaboration, positioning the park as a key player in advancing agricultural technology globally. Continue Reading DBN Phoenix International Innovation Park, located in the North District of ZGC Science City in Beijing, spans 13.65 acres and offers 160,000 m2 of research and office space. Designed to foster innovation in key areas such as biotechnology, bio-manufacturing, medicine and healthcare, food technology and artificial intelligence, the park aims to become a world-class agricultural technology hub. DBN's vision for the park is to accelerate innovation through an open platform that supports startups and established companies alike. The park's "Industry leader + Research + Investment" model leverages DBN's strengths in technological innovation to build a shared, collaborative ecosystem. By capitalizing on its leadership in technological innovation, focusing on industrial applications, and relying on a strong foundation in R&D, the park brings together top-tier agricultural biotech projects to drive collective growth. The park offers innovative R&D facilities and access to top-tier innovation platforms, positioning itself as a key player in the rapidly evolving agricultural technology landscape. As part of its ongoing efforts, DBN Group is developing the ZGC BioIntelligent Manufacturing Innovation Center, focusing on synthetic biology, gene editing, proteomics, AI protein design, healthcare, and artificial intelligence. The center will partner with leading global scientists and industry players to create an innovation ecosystem. Current partners include unicorns like Bluepha, MEGAROBO, and BioMap, as well as rising stars like Microcyto, PhaBuilder, DPTechnology and MoleculeMind. The park is also collaborating with innovative companies such as BioGeometry, Oxsyns, Biocretech, Nobel Prize commercialization projects like Molefuture and IPO-bound firms like Tsingke Biotechnology. Major listed companies like Genliduo Bio-tech, Angel Yeast, and Huaheng Biotechnology have also joined. DBN is actively seeking global AI-driven life sciences projects to build a biomanufacturing industry cluster. The area hosts over 10,000 national high-tech enterprises, 50 unicorns, 270 listed companies, and 200 national-level research institutes, creating a first-class R&D environment. The park offers comprehensive services across various sectors, including financial technology, innovation, international exchange, talent management, and infrastructure services, creating a one-stop platform that supports the full lifecycle of agricultural biotech innovation projects. "DBN has been constantly committed to driving global agricultural advancement through technological innovation," said Vivian Liu, Director of International Cooperation Platform of DBN. "DBN Phoenix International Innovation Park is a key step in our future development, and we look forward to collaborating with innovators and companies worldwide to build a new frontier in agricultural science and drive industry transformation." For more information, please visit the LinkedIn, Facebook(Meta), Instagram, YouTube, and Twitter pages of DBN. Please click here to check the original video: DBN Website: CONTACT: [email protected] SOURCE DBN Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

EMERYVILLE, Calif., Oct. 3, 2024 /PRNewswire/ -- Amyris, a vertically integrated synthetic biology company and a leading innovator in the field of industrial biotechnology, today announced it has been awarded an agreement through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-C) for $12.3 million from the Administration for Strategic Preparedness and Response's (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to advance innovative pharmaceutical manufacturing in the United States. Using Amyris' advanced technology in organism engineering, advanced precision fermentation, synthetic chemistry, process expertise, and manufacturing, Amyris aims to develop up to three small molecule drugs over the next two years – all of which are on the FDA drug shortage list. Based on the achievement of technology development and other milestones, IBMSC and Amyris will jointly decide which drug targets to advance to sample production. During the agreement term, Amyris will explore partnerships with GMP-manufacturing capabilities and market access to bring fully developed drugs to market. "Amyris has consistently pushed the boundaries of what is possible in industrial biotechnology," commented Kathy Fortmann, CEO of Amyris. "With our strong focus on cutting-edge science and automation, the company has developed a robust pipeline of innovative products and technologies, and this IBMSC funding will accelerate our R&D efforts to bring active pharmaceutical ingredients to market, with a focus on delivering impactful outcomes." This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Center for Industrial Base Management and Supply Chain (IBMSC), under Other Transaction Authority Agreement number #75A50123D00003. About Amyris Amyris is a vertically-integrated, synthetic biology company that creates sustainable, market-ready ingredients utilizing proprietary advanced precision fermentation technology and world-class platforms. Leveraging two decades of experience, Amyris collaborates with companies to co-create innovative ingredients at unprecedented speed and scale. This enables partners to deliver products with differentiated performance that meet sustainability and economic objectives. Its renewable and traceable ingredients are included in thousands of products from the world's top brands, reaching millions of consumers. For more information, please visit . About the BioMaP consortium The Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) is a multiple-purpose acquisition vehicle comprised of industry partners across the drug and vaccine manufacturing supply chain, including, but not limited to, drug substance manufacturers of required raw materials and consumables, suppliers of fill-finish services, and developers of innovative manufacturing technologies. The BioMaP-Consortium brings together pharmaceutical, medical, academic, and scientific organizations working toward successful development and delivery of medical countermeasure materials and products. Cooperative partnerships are maintained to ensure that there are adequate manufacturing capabilities to provide and make available requisite products and materials, so that countermeasures and therapies can be delivered to civilian populations addressing threats to the nation's public health or other security interests. The BioMaP-Consortium is also focused on expanding the United States' domestic industrial and manufacturing base for medical countermeasures. Amyris Media Contact: Michael Leavell, SVP R&D Email: [email protected] Website: SOURCE Amyris, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED